| Methods |
A Multicentre, randomised, double‐blind, parallel group, placebo‐controlled, phase IIb efficacy and safety study of adjunctive AZD6765 in patients with major depressive disorder (MDD) and a history of inadequate response to antidepressants |
| Participants |
Male or female patients aged 18 to 70 years, inclusive. The patient must have a clinical diagnosis of major depressive disorder with a lifetime history of inadequate response to at least 3 antidepressants |
| Interventions |
Arm 1: 50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by IV infusion; Arm 2: 100 mg (AZD6765 Solution for Infusion, 1.0 mg/mL) by IV infusion; Arm 3: 0.9 sodium chloride [normal saline] solution for injection by IV infusion |
| Outcomes |
Change from baseline to Week 6 in the Montgomery‐Asberg Depression Rating Scale (MADRS) total score. Time frame: will be scored at weeks 1 (baseline), 2, 3, 4, 5 and 6 |
| Notes |
|
